Longeveron (LGVN) Non-Current Debt (2021)

Longeveron (LGVN) recorded quarterly Non-Current Debt of $5.0 million in Q4 2021.

Longeveron (LGVN) Non-Current Debt (2021) Analysis & Trends

Longeveron's Non-Current Debt history runs 1 years deep, the most recent figure standing at $5.0 million for Q4 2021.

In Q4 2021, Non-Current Debt changed N/A year-over-year to $5.0 million; the TTM figure through Dec 2021 stood at $5.0 million (changed N/A YoY), while the FY2021 annual figure was $5.0 million, changed N/A from the prior year.
Non-Current Debt was $5.0 million for Q4 2021 at Longeveron.
In the past five years, Non-Current Debt ranged from a high of $5.0 million in Q4 2021 to a low of $5.0 million in Q4 2021.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	319.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Longeveron	20.35 Bn	20.33 Bn	264,000.00	-

Historic Data

Download Data

Date	Value
Dec 31, 2021	5.00 Mn
Dec 31, 2021	5.00 Mn